Eli Lilly and Company $LLY is Sanders Morris Harris LLC’s 7th Largest Position

Sanders Morris Harris LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 18.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,198 shares of the company’s stock after selling 1,404 shares during the period. Eli Lilly and Company makes up 4.3% of Sanders Morris Harris LLC’s investment portfolio, making the stock its 7th largest holding. Sanders Morris Harris LLC’s holdings in Eli Lilly and Company were worth $7,434,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of LLY. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after buying an additional 635,358 shares in the last quarter. Morgan Stanley grew its position in shares of Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares during the period. Capital World Investors increased its stake in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after acquiring an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after acquiring an additional 1,432,069 shares during the period. 82.53% of the stock is owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat: Revenue rose 48% year over year to $22.97 billion, surpassing the approximately $20.7 billion consensus estimate. Non-GAAP EPS was $8.38 versus expectations of about $6.06, while reported EPS was $7.94. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand drove growth: Mounjaro and Zepbound sales surged, with Mounjaro reportedly up 91% and the two products generating nearly two-thirds of quarterly revenue. Continued volume growth in diabetes and obesity treatments was the primary catalyst for the stock’s advance. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
• Positive Sentiment: Outlook raised: Lilly increased 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and maintained EPS guidance of $35.50-$36.50. The improved outlook indicates management expects momentum to continue. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Additional commercial and pipeline support: CVS Health expanded its weight-management program through a Lilly partnership, while Lilly is widening early access to experimental obesity drug retatrutide. The FDA also granted breakthrough therapy designation to investigational cancer drug olomorasib, adding longer-term pipeline potential.
• Neutral Sentiment: Key investor concern: Management indicated that manufacturing capacity could become a bottleneck if GLP-1 demand continues to outpace supply. Lilly is working to expand production, but execution and competition remain important risks at the stock’s elevated valuation.

Eli Lilly and Company Stock Up 4.9%

Shares of Eli Lilly and Company stock opened at $1,170.30 on Thursday. The company has a 50-day simple moving average of $1,156.45 and a two-hundred day simple moving average of $1,045.49. The stock has a market capitalization of $1.10 trillion, a PE ratio of 41.57, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $2.22. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.69 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts anticipate that Eli Lilly and Company will post 34.71 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Sanford C. Bernstein raised their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Finally, Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.